Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-BN WEV
- Development stage
- Phase 2
- Lead developer
- Bavarian Nordic
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-BN WEV is a prophylactic, trivalent vaccine candidate developed using the Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN) platform. It is designed to provide active immunization against three equine encephalitis viruses—Western (WEEV), Eastern (EEEV), and Venezuelan (VEEV)—which are mosquito-borne alphaviruses capable of causing severe and potentially fatal neurological disease in humans. The vaccine encodes the envelope surface proteins of all three viruses to induce both humoral and cellular immune responses. Clinical studies have shown that it is well tolerated, immunogenic, and induces robust neutralizing antibody responses after two doses. There are currently no approved vaccines for these diseases in humans[1][2][8].
- Brand names
- MVA-BN WEV
- Other names
- Equine encephalitis virus vaccine - Bavarian NordicMVA BN WEV
02
Targets
EEEV envelope glycoprotein (Eastern equine encephalitis virus envelope glycoprotein)VEEV envelope glycoprotein (Venezuelan equine encephalitis virus envelope glycoprotein)WEEV E1/E2 (Western equine encephalitis virus envelope glycoproteins)Western equine encephalitis virus glycoprotein
Beyond the preview
Go deeper on MVA-BN WEV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-BN WEV.